Summary of Study ST001135
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000760. The data can be accessed directly via it's Project DOI: 10.21228/M8FH6C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001135 |
Study Title | Different dose exposure of OPC-163493 on HepG2 cells (part-I) |
Study Type | Compound dosage test |
Study Summary | Metabolomics analysis were on 8 samples of HepG2 cells that were treated with compound OPC-163493 (DMSO control, 1, 3, or 10µM; each n=2) exposure for 30 min. |
Institute | Otsuka Pharmaceutical Co., Ltd. |
Last Name | Kanemoto |
First Name | Naohide |
Address | 463-10 Kagasuno Kawauchi-cho Tokushima 771-0192, Japan |
Kanemoto.Naohide@otsuka.jp | |
Phone | 81-03-6717-1400 |
Submit Date | 2019-02-07 |
Analysis Type Detail | LC-MS |
Release Date | 2019-03-06 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment |
---|---|---|
SA078229 | OPC-0uM-5 | - |
SA078230 | OPC-0uM-1 | - |
SA078231 | OPC-1uM-2 | 1 |
SA078232 | OPC-1uM-6 | 1 |
SA078235 | OPC-10uM-8 | 10 |
SA078236 | OPC-10uM-4 | 10 |
SA078233 | OPC-3uM-3 | 3 |
SA078234 | OPC-3uM-7 | 3 |
Showing results 1 to 8 of 8 |